Provectus Biopharmaceuticals’ Poster Presentation on PV-10 Clinical Data from Phase 1 Study for Cancers of the Liver Schedu...
May 14 2015 - 4:04PM
Business Wire
Presentation Set for 10:30 to 11:00 a.m. and
4:55 to 5:25 p.m. Local Time
ESMO’S World Congress on Gastrointestinal
Cancer Runs July 1-4, 2015, in Barcelona, Spain
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT,
http://www.pvct.com), a clinical-stage oncology and dermatology
biopharmaceutical company (“Provectus” or the “Company”), announced
today that the abstract titled, "Phase 1 Study of PV-10 for
Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the
Liver," to be presented at the European Society for Medical
Oncology’s 17th World Congress on Gastrointestinal Cancer, is
scheduled for Thursday, July 2, 2015 from 10:30 to 11:00 a.m. and
4:55 to 5:25 p.m. local time. Sanjiv S. Agarwala, MD, of St. Luke's
University Hospital and Health Network, Bethlehem, PA, will be the
presenter.
Dr. Craig Dees, PhD, CEO of Provectus, said, "We are very
pleased that Dr. Agarwala will be presenting this important
information to the World Congress on Gastrointestinal Cancer. While
our research into PV-10 as a treatment for melanoma continues, we
are equally committed to determining its safety and efficacy in the
treatment of other types of cancer. We are optimistic that PV-10
will prove to be a useful weapon against a wide variety of
cancers.”
The ESMO 17th World Congress on Gastrointestinal Cancer will run
from July 1 – 4, 2015 in Barcelona, Spain.
PV-10, a 10% solution of Rose Bengal that is currently being
investigated as a potential cancer therapeutic, is designed for
injection into solid tumors (intralesional administration).
About the European Society for Medical Oncology
The European Society for Medical Oncology (ESMO) is the leading
European professional organization committed to advancing the
specialty of medical oncology and promoting a multidisciplinary
approach to cancer treatment and care.
ESMO's mission is to advance cancer care and cure through
fostering and disseminating good science that leads to better
medicine and determines best practice.
ESMO's scientific journal, Annals of Oncology, ranks among the
top clinical oncology journals worldwide. ESMO events are the
meeting place in Europe for medical oncologists to update their
knowledge, to network and to exchange ideas.
To find out more about ESMO, please
visit: www.esmo.org.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc. specializes in developing
oncology and dermatology therapies. PV-10, its novel
investigational drug for cancer, is designed for injection into
solid tumors (intralesional administration), thereby reducing
potential for systemic side effects. Its oncology focus is on
melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has
completed phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company’s other
clinical trials, including its current phase 3 study in melanoma,
can be found at the NIH registry, www.clinicaltrials.gov. For
additional information about Provectus, please visit the Company’s
website at www.pvct.com or contact Porter, LeVay & Rose,
Inc.
FORWARD-LOOKING STATEMENTS: This release contains
“forward-looking statements” as defined under U.S. federal
securities laws. These statements reflect management’s current
knowledge, assumptions, beliefs, estimates, and expectations and
express management’s current views of future performance, results,
and trends and may be identified by their use of terms such as
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “will,” and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2014) and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with the
fully enrolled phase 3 trial of PV-10 to treat locally advanced
cutaneous melanoma and the costs associated with such a trial if it
is necessary to complete (versus interim data alone);
- our determination whether to license
PV-10, our melanoma drug product candidate, and other solid tumors
such as cancers of the liver, if such licensure is appropriate
considering the timing and structure of such a license, or to
commercialize PV-10 on our own to treat melanoma and other solid
tumors such as cancers of the liver;
- our ability to license our dermatology
drug product candidate, PH-10, on the basis of our phase 2 atopic
dermatitis and psoriasis results, which are in the process of being
further developed in conjunction with mechanism of action studies;
and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper, CFO,
COO866-594-5999 #30orPorter, LeVay & Rose, Inc.Marlon Nurse,
DM, SVP – Investor Relations212-564-4700orBill Gordon – Media
Relations212-724-6312
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024